ReviewOncoimmunology2014
Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors.
Review in Oncoimmunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review.Human vaccines & immunotherapeutics · 2014Pooled it
- Circulating immune landscape in melanoma patients undergoing anti-PD1 therapy reveals key immune features according to clinical response to treatment.Frontiers in immunology · 2024Article
- Nonsurgical Treatment Strategies for Elderly Head and Neck Cancer Patients: An Emerging Subject Worldwide.Cancers · 2022Review
- Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes.Clinical & translational immunology · 2021Article
- Nomograms to Predict the Density of Tumor-Infiltrating Lymphocytes in Patients With High-Grade Serous Ovarian Cancer.Frontiers in oncology · 2021Article
- Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment.World journal of clinical cases · 2020Article
- Potent Bidirectional Cross-Talk Between Plasmacytoid Dendritic Cells and γδT Cells Through BTN3A, Type I/II IFNs and Immune Checkpoints.Frontiers in immunology · 2020Article
- MiR-217 Inhibits M2-Like Macrophage Polarization by Suppressing Secretion of Interleukin-6 in Ovarian Cancer.Inflammation · 2019Article
- Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.JAMA network open · 2019Article
- Crisis or self-correction: Rethinking media narratives about the well-being of science.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors.Annals of translational medicine · 2018Article
- Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2016Article
- Engineered Mesenchymal Stem Cells as an Anti-Cancer Trojan Horse.Stem cells and development · 2016Article
- Decreased expression of hyaluronan synthase 1 and 2 associates with poor prognosis in cutaneous melanoma.BMC cancer · 2016Article
- Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15.Frontiers in immunology · 2016Article
- IL-27 induces the expression of IDO and PD-L1 in human cancer cells.Oncotarget · 2015Article
- A sequence-specific DNA binding small molecule triggers the release of immunogenic signals and phagocytosis in a model of B-cell lymphoma.Quarterly reviews of biophysics · 2015Review
- Characterization of theOncoimmunology · 2015Article
- Tumor infiltrating lymphocytes in ovarian cancer.Cancer biology & therapy · 2015Review
- Novel immune checkpoint blocker approved for the treatment of advanced melanoma.Oncoimmunology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating data from patients treated with checkpoint inhibitors and other immunomodulatory agents indicate that harnessing the power of the immune system is integral to achieve improve long-term cancer containment rates and prolong patient survival. Due to their mechanism of action, immunotherapeutic approaches have the potential to be effective against almost every tumor type. Durable responses to immunotherapy and prolonged patient survival have indeed been documented in individuals with melanoma, as well as kidney and lung cancer. These advances call for the re-evaluation of how clinical benefit is measured in an era in which long-term tumor control and survival are achievable treatment goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.